

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
6 June 2002 (06.06.2002)

PCT

(10) International Publication Number  
**WO 02/44151 A1**(51) International Patent Classification<sup>7</sup>: **C07D 209/48**, (54) Common Representative: DESHMUKH, Jayadeep, R.; A61K 31/40, A61P 13/08 Ranbaxy Laboratories Limited, 600 College Road East, Suite 2100, Princeton, NJ 08540 (US).(21) International Application Number: **PCT/IB01/02261**

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date:  
29 November 2001 (29.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
1097/DEL/2000 30 November 2000 (30.11.2000) IN(71) Applicant (for all designated States except US): **RAN-BAXY LABORATORIES LIMITED [IN/IN]**; 19, Nehru Place, New Delhi 110 019 (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ANAND, Nitya [IN/IN]**; B-62, Nirala Nagar, Lucknow 226 007, Uttar Pradesh (IN). **JAIN, Sanjay [IN/IN]**; Flat No. 3, 1st Floor, Madhav Residency, Marutra, Gayekvad Nagar, 7 Aundh, Pune (IN). **SINHA, Neelima [IN/IN]**; D-5, DSIR Colony, Nirala Nagar, Lucknow 226 007, Uttar Pradesh (IN). **CHUGH, Anita [IN/IN]**; RA-36, Inder Puri, New Delhi 110 012 (IN). **HEGDE, Laxminarayan, G. [IN/IN]**; 790, Sector-A, Pocket-C, Vasant Kunj, New Delhi 110 070 (IN). **GUPTA, Jang, Bahadur [IN/IN]**; 349, Sector-14, Gurgaon 122 001, Haryana (IN).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**WO 02/44151 A1**(54) Title: **1,4-DISUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS URO-SELECTIVE SG(A)1-ADRENOCEPTOR BLOCKERS**(57) Abstract: The present invention relates to a novel 1,4-disubstituted piperazine derivatives of Formula I, and their pharmaceutically acceptable acid addition salts having excellent uro-selective  $\alpha$ 1-adrenoceptor antagonistic activity exceeding those of previously described compounds. The compounds of the present invention hold promise for treating the symptoms of benign prostatic hyperplasia (BPH). The invention also relates to methods for making the novel compounds, pharmaceutical compositions containing the compounds, and method of treating the symptoms of benign prostatic hyperplasia using the compounds.

## 1,4-DISUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS URO-SELECTIVE ALPHA<sub>1</sub>-ADRENOCEPTOR BLOCKERS

### FIELD OF THE INVENTION

5 The present invention relates to certain novel 1,4-disubstituted piperazine derivatives of Formula I,



### **FORMULA - I**


10 and their pharmaceutically acceptable acid addition salts having excellent uro-selective  $\alpha_1$ -adrenoceptor antagonistic activity exceeding those of previously described compounds. The compounds of the present invention hold promise for treating the symptoms of benign prostatic hyperplasia (BPH). The invention also relates to methods for making the novel compounds, 15 pharmaceutical compositions containing the compounds, and method of treating the symptoms of benign prostatic hyperplasia using the compounds.


### BACKGROUND OF THE INVENTION

Benign prostatic hyperplasia (BPH) is a common disease in aging males and a substantial percentage of men with BPH develop a bladder 20 obstruction. The obstruction caused by BPH is thought to be attributable to two main components i.e. a static component related to enlarged prostatic tissue mass and a dynamic component involving excessive contraction of prostate and urethra. The most successful therapies are based on  $\alpha$ -

adrenergic receptor antagonism and androgen levels modulation by 5 $\alpha$ -reductase inhibitors. 5 $\alpha$ -reductase inhibitors are of limited effectiveness in terms of immediate symptomatic and urodynamic relief.  $\alpha_1$ -adrenergic receptors antagonists appear to be much more effective and provide 5 immediate subjective symptomatic improvements and are, therefore, the preferred modalities of treatment in the control of symptoms of benign prostatic hyperplasia.  $\alpha_1$ -Adrenoceptors are also present in blood vessels and play an important role in the regulation of blood pressure. Thus  $\alpha_1$ -adrenoceptor antagonists are of particular importance as they were originally 10 developed as antihypertensive agents and are likely also to have a beneficial effect on lipid dysfunction and insulin resistance, which are commonly associated with essential hypertension.


The drugs most often used for BPH are the long acting  $\alpha_1$ -adrenoceptor antagonists, terazosin, doxazosin and tamsulosin, as shown 15 below:





DOXAZOSIN

5



(R)-(-)-TAMSULOSIN

10 However, these drugs are associated with vascular side effects (e.g. postural hypertension, syncope, dizziness, headache etc.) due to lack of selectivity of action between prostatic and vascular  $\alpha_1$ -adrenoceptors.


Over the past decade, there has been an intensive search for "uroselective"  $\alpha_1$ -adrenoceptor antagonists for BPH, which would avoid the 15 cardiovascular side effects, associated with currently used drugs. Clearly,  $\alpha_1$ -adrenoceptor antagonists which have inherently greater selectivity for prostatic  $\alpha_1$ -adrenoceptors offer the potential of increased urodynamic benefits. This underscores the importance of the discovery of antagonists which will confer urodynamic improvement without the side effects associated 20 with existing drugs.

Recently, three subtypes of  $\alpha_1$ -receptors namely  $\alpha_{1A}$ ,  $\alpha_{1B}$ , and  $\alpha_{1D}$  have been identified which can provide a key development to improve the pharmacological selectivity of  $\alpha_1$  blockers. These subtypes have different tissue distribution with the  $\alpha_{1A}$  receptors predominating lower urinary tract tissue and less prevalent in the vasculature. This makes it possible to develop agents with selective action against pathological urodynamic states.

A uroselective  $\alpha_{1A}$ -antagonist could have greater efficacy if dose escalation is not limited to cardiovascular side effects and a more complete blockade of prostatic  $\alpha_1$ -adrenoceptors could be attained. Compounds have been evaluated for potency against agonist or stimulation-induced increase in urethral pressure relative to blood pressure reduction or blockade of agonist-induced blood pressure. Many selective antagonists have been described by Hieble et al in Exp opin Invest Drugs; 6, 367-387 (1997) and by Kenny et. al. in J. Med. Chem.; 40, 1293 - 1315 (1997). Structure activity relationships in many of these structural series have been studied in details and numerous highly selective compounds have been identified.

The present invention is directed to the development of novel  $\alpha_1$ -antagonists, namely, 1,4-disubstituted piperazine compounds, with greater selectivity of action against  $\alpha_{1A}$ -adrenoceptors and which would thus offer relief from the symptoms of BPH.

There are many description in the literature about the pharmacological activities associated with phenyl piperazines, Eur. J. Med. Chem. - Chimica Therapeutica, 12, 173-176 (1977), describes substituted trifluoromethyl phenyl piperazines having cyclo-imido alkyl side chains shown below.



5 These compounds are potential anorectic agents with no CNS side effects. Other related compounds which have been prepared as anxiolytic, neuroleptic, anti-diabetic and anti-allergic agents are described in the following references:

- Yukihiro et al; PCT Appl. WO 98/37893 (1998).
- 10 - Steen et al; *J. Med. Chem.*, 38, 4303-4308 (1995).
- Ishizumi et al. *Chem. Pharm. Bull.*, 39 (9), 2288-2300 (1991).
- Kitaro et al; JP 02-235865 (1990).
- Ishizumi et al; US 4,598,078 (1986).
- 15 - New et. al; *J. Med. Chem.*, 29, 1476-1482 (1986).
- Shigeru et al, JP 60-204784 (1985).
- New et al, US 4,524,206 (1985).
- Korgaonkar et al; *J. Indian Chem. Soc.*, 60, 874-876 (1983)

The synthesis and pharmacology of some 2-[3-(4-aryl-1-piperazinyl)propyl]-1H-benz(de) isoquinolin-1,3-(2H)-diones/2,5-pyrrolidinediones (J. Indian. Chem. Soc., Vol., LXIII, 529-530 (1986), of N-(N<sup>4</sup>-aryl-N<sup>1</sup>-piperazinylmethyl)-4-(4-methoxyphenyl)piperidine-2,6-diones [J. Indian Chem. Soc., Vol. LV, 819-821 (1978)], and of N-(N<sup>4</sup>-arylpiperazinylalkyl)-phthalimides (J. Indian. Chem. Soc., Vol. LVI, 1002-1005 (1979)]) have been reported. The compounds were shown to exhibit antihypertensive and CNS depressant activity in experimental animals.

However, none of the above mentioned references disclose or suggest 10 the selective  $\alpha_1$  -adrenoceptor blocking activity of the compounds disclosed therein and thus their usefulness in the treatment of symptoms of benign prostate hyperplasia did not arise.

The synthesis of 1-(4-arylpiperazin-1-yl)- $\omega$ -[N-( $\alpha$ ,  $\omega$ -dicarboximido)]-alkanes useful as uro-selective  $\alpha_1$ -adrenoceptor blockers are disclosed in US 15 Patent Nos. 6,083,950 and 6,090,809. These compounds had good  $\alpha_1$ -adrenergic blocking activity and selectivity and one of the compounds is in phase II clinical trials.

It has now been discovered that structural modification of these compounds from glutarimide to tetrahydrophthalimide enhances the 20 adrenoceptor blocking acitivity and also greatly increases the selectivity for  $\alpha_{1A}$  in comparison to  $\alpha_{1B}$  - adrenoceptor blocking activity, an essential requirement for compounds to be good candidates for treatment of BPH.

### OBJECTS OF THE INVENTION

An object of the present invention is to provide novel arylpiperazine derivatives that exhibit greater  $\alpha_{1A}$ -adrenergic blocking potency and more selectivity than available known compounds and are useful for treatment of  
5 benign prostatic hyperplasia.


It is also an object of the invention to provide a method for synthesis of the novel compounds.

It is a further object of the present invention to provide compositions containing the novel compounds which are useful in the treatment of benign  
10 prostatic hyperplasia.

### SUMMARY OF THE INVENTION

The above-mentioned objectives are achieved by a novel class of piperazine derivatives of general Formula I, as shown below,

15



### **FORMULA - I**

its pharmaceutically acceptable salts, amides, enantiomers, diastereomers, N-oxides, prodrugs, metabolites or their polymorphs, wherein A is a straight or branched C<sub>1</sub>-C<sub>4</sub> alkyl chain; R is cinnamyl, benzyl, substituted benzyl, phenyl,  
20 mono- or disubstituted phenyl group substituted with the substituents independently selected from the group consisting of halogen, hydroxy, C<sub>1</sub>-C<sub>6</sub>

alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, trifluoromethyl, nitro and trifluoroalkoxy group, or (dihalodiphenyl) methyl.

Halogen of Formula I may be selected from the group consisting of chloro, fluoro, iodo; C<sub>1</sub>-C<sub>6</sub> alkyl may be selected from methyl, ethyl, n-propyl, 5 isopropyl, butyl, tert-butyl; and C<sub>1</sub>-C<sub>6</sub> alkoxy may be selected from methoxy, ethoxy, n-propoxy, isopropoxy, or hexyloxy.

The present invention also provides pharmaceutical compositions for the treatment of benign prostatic hyperplasia. These compositions comprise an effective amount of at least one of the compounds of Formula I, or an 10 effective amount of at least one physiologically acceptable acid addition salt thereof, with a pharmaceutically acceptable carrier.

An illustrative list of particular compounds of the invention is given below:

Compound

No.	Name
1.	2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
2.	2-[3-{4-(3-Chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
3.	2-[3-{4-(2-Methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
4.	2-[3-{4-(4-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
5.	2-[3-{4-(3-Trifluoromethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;

No.	Name
6.	2-[3-{4-(2-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
7.	2-[3-{4-(3,4-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
8.	2-[3-{4-(2-Methoxy-5-fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
9.	2-[3-{4-(2-Ethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
10.	2-[3-{4-(2,4-Difluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
11.	2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
12.	2-[3-{4-(2-Methyl-5-chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
13.	2-[3-{4-(Phenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
14.	2-[3-{4-(Benzyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
15.	2-[3-{4-(Cinnamyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
16.	2-[3-{4-(4-Nitrophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
17.	2-[3-{4-(3-Chloro-4-methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
18.	2-[3-{4-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
19.	2-[3-{4-(Bis-4-fluorophenyl)methylpiperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
20.	2-[3-{4-(2,4-Dichlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
21.	2-[3-{4-(2,4-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;

No.	Name
22.	2-[3-{4-(2,6-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
23.	2-[3-{4-(2-Isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
24.	2-[3-{4-(2-Propoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
25.	2-[3-{4-(2-n-Hexyloxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
26.	2-[3-{4-(2,5-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
27.	2-[3-{4-(4-tert-Butylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
28.	2-[3-{4-(2-Methoxy-6-hydroxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
29.	2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
30.	2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-2-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
31.	2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;

#### DETAILED DESCRIPTION OF THE INVENTION


The compounds of the present invention may be prepared by one of the reaction sequences (Schemes I and II) shown below to yield compounds 5 of Formula I wherein A is a straight or branched C<sub>1</sub>-C<sub>4</sub> alkyl chain; R is cinnamyl, benzyl, substituted benzyl, phenyl, mono- or disubstituted phenyl group substituted with the substituents independently selected from the group

consisting of halogen, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, trifluoromethyl, nitro and trifluoroalkoxy group, or (dihalodiphenyl) methyl.

**Scheme I**


The compounds of the Formula I can be prepared by condensation of  
 5 piperazine derivatives of Formula III with the anhydride of Formula II, wherein  
 A and R are the same as defined above, preferably in a solvent selected from  
 the group consisting of pyridine, n-butanol, benzene and xylene while  
 refluxing.

**SCHEME - I**



**Scheme II**

The compounds of the Formula I, wherein A and R are the same as defined above, can also be synthesized following the reaction sequence as shown in Scheme II, by condensation of 1-( $\omega$ -haloalkyl)-cis-3a,4,7,7a-5 tetrahydrophtalimide of Formula IV, wherein A is the same as defined above, with 1-substituted piperazine of the Formula V, wherein R is the same as defined before.

**SCHEME - II**

Pharmaceutically acceptable, non toxic, acid addition salts of the compounds prepared according to the present invention having the utility of the free bases of Formula I may be formed with inorganic or organic acids, by methods well known in the art and may be used in place of the free bases.

5 Representative examples of suitable acids for formation of such acid addition salts are malic, fumaric, benzoic, ascorbic, pamoic, succinic, bismethylene, salicylic, methanesulphonic ethanesulphonic, acetic, propionic, tartaric, citric, gluconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfamic, phosphoric, hydrobromic, sulfuric, hydrochloric, 10 and nitric acids, and the like.

The present invention also includes within its scope prodrugs of the compounds of Formula I. In general, such prodrugs will be functional derivatives of these compounds which are readily converted in vivo into the defined compounds. Conventional procedures for the selection and 15 preparation of suitable prodrugs are known.

The invention also includes the enantiomers, diastereomers, N-oxides, pharmaceutically acceptable salts, amides and polymorphic forms of these compounds, as well as metabolites having the same activity. The invention further includes pharmaceutical compositions comprising the molecules of 20 Formula I, or prodrugs, metabolites, enantiomers, diastereomers, N-oxides, pharmaceutically acceptable salts or polymorphic forms thereof, in combination with a pharmaceutically acceptable carrier and optionally included excipients.

In yet another aspect, the invention is directed to methods for selectively blocking  $\alpha_{1A}$  receptors by delivering in the environment of said receptors, e.g. to the extracellular medium (or by administering to a mammal possessing said receptors) an effective amount of the compounds of the 5 invention.

While the invention has been described by reference to specific embodiments, this was for purposes of illustration only. Numerous alternative embodiments will be apparent to those skilled in the art and are deemed to be within the scope of the invention.

10 The examples mentioned below demonstrate the general synthetic as well as the specific preparation for the preferred compound. The examples are given to illustrate the details of the invention and should not be constrained to limit the scope of the present invention.

#### EXAMPLE

15 Preparation of 2-[3-[4-(2-methoxyphenyl)piperazine-1-yl]propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione.

#### Scheme I

A mixture of 1-amino-3-[4-(2-methoxyphenyl)piperazine-1-yl]propane (0.498g, 2.0 mmol) and cis-1,2,3,6-tetrahydrophthalic anhydride (0.273g, 20 1.8mmol) was refluxed in pyridine (10ml) for about 5 hrs. After the reaction was over, solvent was removed under vacuum and the residue was dissolved in chloroform (25ml). The chloroform phase was washed with water (2 x

15ml), dried over anhydrous sodium sulphate and concentrated under vacuum. The crude compound so obtained was purified by column chromatography over silica gel (100-200 mesh) using chloroform as an eluent (yield = 0.502g, 72%).

5 The hydrochloride salt was prepared by the addition of molar quantity of ethereal hydrogen chloride solution to the ethereal solution of free base and collected the precipitated solid by filtration (m.p. 184-185°C).

### **Scheme II**

A mixture of 1-(3-bromopropyl)-cis-3a, 4,7,7a-tetrahydronaphthalimide (7.04g, 25.88 mmol), 1-(2-methoxyphenyl)piperazine hydrochloride (5.32g, 23.29 mmol), potassium carbonate (7.14g, 51.76mmol) and potassium iodide (0.026g, 1.55mmol) in N, N-dimethylformamide (27ml) was heated at 75-80°C for about 12 hours. After the reaction was over, solvent was evaporated under vacuum, residue was suspended in water (130ml) and extracted the compound with dichloromethane (2 x 65ml). The combined dichloromethane layer was washed with water (2 x 30ml), dried over anhydrous sodium sulphate and concentrated the solvent under vacuum to yield 8.308g (93%) of the crude base. The compound so obtained was converted into its hydrochloride salt (m. pt. 184-185°C).

20 An illustrative list of the compounds of the invention which were synthesised by one or more of the above described methods is now given.

## Compound

No.	Name
1.	2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 184-185°C.
2.	2-[3-{4-(3-Chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 221-223°C.
3.	2-[3-{4-(2-Methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 186-187°C.
4.	2-[3-{4-(4-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 228-230°C.
5.	2-[3-{4-(3-Trifluoromethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 215-217°C.
6.	2-[3-{4-(2-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 203-204°C.
7.	2-[3-{4-(3,4-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 194-196°C.
8.	2-[3-{4-(2-Methoxy-5-fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 163-165°C.
9.	2-[3-{4-(2-Ethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 232.5-233.5°C.
10.	2-[3-{4-(2,4-Difluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 218.2-219°C.
11.	2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 221.9 - 222.7°C.
12.	2-[3-{4-(2-Methyl-5-chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 231-232°C.
13.	2-[3-{4-(Phenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 231-232°C.
14.	2-[3-{4-(Benzyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 275-276°C.
15.	2-[3-{4-(Cinnamyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 263-265°C.

No.	Name
16.	2-[3-{4-(4-Nitrophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.259.5 - 261°C.
17.	2-[3-{4-(3-Chloro-4-methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.248-249°C.
18.	2-[3-{4-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.232-233°C.
19.	2-[3-{4-(Bis-4-fluorophenyl)methylpiperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.235-236°C.
20.	2-[3-{4-(2,4-Dichlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.210-211°C.
21.	2-[3-{4-(2,4-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.226-227°C.
22.	2-[3-{4-(2,6-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.223-224°C.
23.	2-[3-{4-(2-Isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.223-224°C.
24.	2-[3-{4-(2-Propoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.193-194°C.
25.	2-[3-{4-(2-n-Hexyloxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.165-166°C.
26.	2-[3-{4-(2,5-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 193-195°C.
27.	2-[3-{4-(4-tert-Butylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 264-265°C.
28.	2-[3-{4-(2-Methoxy-6-hydroxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.267-268°C.
29.	2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.219-220°C.
30.	2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-2-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 184-185°C.
31.	2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.246-248°C.

All the melting points reported above are uncorrected and measured by an open capillary method using Buchi 535.

## PHARMACOLOGICAL TESTING RESULTS

### Receptor Binding Assay

5 Receptor binding assays were performed using native α-adrenoceptors. The affinity of different compounds for α<sub>1A</sub> and α<sub>1B</sub> adrenoceptor subtypes was evaluated by studying their ability to displace specific [<sup>3</sup>H]prazosin binding from the membranes of rat submaxillary and liver respectively (*Michel et al, Br J Pharmacol, 98, 883-889 (1989)*). The 10 binding assays were performed according to *U'Prichard et al.(Eur J Pharmacol, 50:87-89 (1978))* with minor modifications.

Submaxillary glands were isolated immediately after sacrifice. The liver was perfused with buffer (Tris HCl 50 mM, NaCl 100 mM, 10 mM EDTA pH 7.4). The tissues were homogenised in 10 volumes of buffer (Tris HCl 50 15 mM, NaCl 100 mM, EDTA 10 mM, pH 7.4). The homogenate was filtered through two layers of wet gauze and filtrate was centrifuged at 500g for 10min. The supernatant was subsequently centrifuged at 40,000g for 45 min. The pellet thus obtained was resuspended in the same volume of assay buffer (Tris HCl 50 mM, EDTA 5mM, pH 7.4) and were stored at -70°C until the time 20 of assay.

The membrane homogenates (150-250 µg protein) were incubated in 250 µl of assay buffer (Tris HCl 50 mM, EDTA 5 mM, pH 7.4) at 24-25°C for

1h. Non-specific binding was determined in the presence of 300 nM prazosin. The incubation was terminated by vacuum filtration over GF/B fibre filters. The filters were then washed with ice cold 50mM Tris HCl buffer (pH 7.4). The filtermats were dried and bound radioactivity retained on filters was 5 counted. The IC<sub>50</sub> & Kd were estimated by using the non-linear curve fitting program using G Pad Prism software. The value of inhibition constant Ki was calculated from competitive binding studies by using Cheng & Prusoff equation (*Cheng & Prusoff, Biochem Pharmacol, 1973,22: 3099-3108*), Ki = IC<sub>50</sub> /(1+L/Kd) where L is the concentration of [<sup>3</sup>H]prazosin used in the 10 particular experiment (Table I).

### **In Vitro Functional Studies**

In order to study selectivity of action of these compounds towards different  $\alpha$ -adrenoceptor subtypes, the ability of these compounds to antagonise  $\alpha_1$  – adrenoceptor agonist induced contractile response on aorta 15 ( $\alpha_1$ <sub>D</sub>prostate ( $\alpha_1$ <sub>A</sub> and spleen ( $\alpha_1$ <sub>B</sub>) was studied. Aorta and spleen tissues were isolated from urethane anaesthetised (1.5gm/kg) male wistar rats. Isolated tissues were mounted in organ bath containing Krebs Henseleit buffer of following composition (mM) : NaCl 118; KCl 4.7; CaCl<sub>2</sub> 2.5; MgSO<sub>4</sub>. 7H<sub>2</sub>O 1.2; NaHCO<sub>3</sub> 25; KH<sub>2</sub>PO<sub>4</sub> 1.2; glucose 11.5. Buffer was maintained at 20 37°C and aerated with a mixture of 95% O<sub>2</sub> and 5% CO<sub>2</sub>. A resting tension of 2g (aorta) or 1g (spleen and prostate) was applied to tissues. Contractile response was monitored using a force displacement transducer and recorded on chart recorders. Tissues were allowed to equilibrate for 2 hours. At the end

of equilibration period, concentration response curves to norepinephrine (aorta) and phenylepinephrine (spleen and prostate) were obtained in absence and presence of tested compound (at concentration of 0.1, 1 and 10 mM). Antagonist affinity was calculated and expressed as pK<sub>B</sub> values in  
5 Table II.

**In Vivo Uroselectivity Study:**

In order to assess the uroselectivity in vivo, the effects of these compounds were studied on mean arterial pressure (MAP) and intraurethral pressure (IUP) in conscious beagle dogs as per the method of Brune et. al.  
10 (*Pharmacol 1996, 53 :356-368*). Briefly, male dogs were instrumented for chronic continuous measurement of arterial blood pressure by implanting a telemetry transmitter (TL11M2-D70-PCT, Data Sci. International, St. Paul, MN. USA) into the femoral artery, two weeks prior to the study. During the recovery period, the animal was acclimatized to stay in the sling restraint. On  
15 the day of testing, overnight fasted animal was placed in the sling restraint. A Swan-Ganz. Balloon tipped catheter was introduced into the urethra at the level of prostate and the balloon was inflated (Brune. et. al. 1996). After recording the base line readings, effect of 16 µg/kg, phenylephrine (i.v.) on MAP and IUP was recorded. The response of phenylephrine to MAP and IUP  
20 were recorded at 0.5, 1, 2, 3, 4, 6, 9 and 24 hours after the oral administration of vehicle or the test drug. The changes in MAP was recorded on line using Dataquest Software (Data Sci. International. St. Paul, MN. USA) and IUP was recorded on a Grass Polygraph (Model 7, Grass Instruments, USA). The change in phenylephrine response on MAP and IUP administration after the

test drug administration was calculated as percent change of that of control values. Area under curve was calculated and the ratio of the values for MAP and IUP was used for calculating the uroselectivity (Table III)

**Table I: Radioligand Binding Studies**

**5 Affinity of compounds for Alpha -1 adrenoreceptor subtypes.**

Compound No.	$\alpha_1 A$ (Rat submaxillary)	$\alpha_1 B$ (Rat liver)	Selectivity $\alpha_1 B/\alpha_1 A$
	Ki (nM)	Ki (nM)	
01	0.8	73	91
02	83	398	4.8
03	32.5	168	5
04	80	363	4.5
05	259	>500	2
06	36	469	13
07	183	>500	2.7
08	0.34	29	85
09	0.3	62	207
10	62	165	2.7
11	0.13	19	146
12	8.66	51.3	5.9
13	6.3	384	61
14	>500	>500	1
15	>500	>500	1
16	>500	>500	1
17	48	37	0.78
18	10	271	27
19	5.26	81	15
20	46.8	>500	11
21	>500	>500	1
22	208	>500	2.4
23	0.16	28	175
24	0.24	28	117
25	3.3	>500	>151
26	38	>500	13
27	>500	>500	1
28	>500	>500	1
29	3.45	708	205
30	48	611	13
31	2.1	232	110

**Table II:****In Vitro Functional Assays:**

Compound No.	$\alpha$ Adrenoceptor Subtype (pK <sub>B</sub> )			Selectivity	
	$\alpha_{1A}$	$\alpha_{1B}$	$\alpha_{1D}$	$\alpha_{1A}/\alpha_{1D}$	$\alpha_{1A}/\alpha_{1B}$
01	9.27	7.66	8.64	4	41
08	8.93	8.40	9.05	-1.31	3.4
09	9.17	7.8	8.6	3.6	23
11	9.95	8.28	8.76	15	47
13	8.04	6.09	7.29	5.6	89
23	9.94	7.71	9.91	1	170
24	10.4	7.85	9.27	13	355
25	8.90	7.17	9.00	-1.26	54
29	7.06	5.8	7.47	-2.57	18
31	8.3	ND	7.79	3.24	

5

**Table III: In Vivo Uroselectivity Studies in Conscious Beagle Dogs**


Compound No.	Dose (µg/kg)	Route	Area Under Curve		Uroselectivity Ratio
			MAP	IUP	IUP/MAP
01	100	p.o.	93	514	5.54
11	10	p.o.	10	661	66
23	3	p.o.	197	790	4
24	3	p.o.	68	522	7.6

10 While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.

**WE CLAIM:**

1. A compound having the structure of Formula I

5



10

**FORMULA - I**

its pharmaceutically acceptable salts, amides, enantiomers, diastereomers, N-oxides, prodrugs, metabolites or their polymorphs, wherein A is a straight or branched C<sub>1</sub>-C<sub>4</sub> alkyl chain; R is cinnamyl, benzyl, substituted benzyl, phenyl, 15 mono- or disubstituted phenyl group substituted with the substituents independently selected from the group consisting of halogen, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, trifluoromethyl, nitro, trifluoroalkoxy group, or (dihalodiphenyl) methyl,

20 2. The compound according to claim 1 wherein halogen is selected from the group consisting of chloro, fluoro, iodo; C<sub>1</sub>-C<sub>6</sub> alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy is selected from the group consisting of methoxy, ethoxy, n-propoxy, isopropoxy, and hexyloxy.

25

3. The compounds according to claim 1 selected from the group consisting of:


- 2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 01).
- 2-[3-{4-(3-Chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 02).
- 2-[3-{4-(2-Methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 03).

- 2-[3-{4-(4-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 04).
- 2-[3-{4-(3-Trifluoromethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 05).
- 2-[3-{4-(2-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 06).
- 2-[3-{4-(3,4-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 07).
- 2-[3-{4-(2-Methoxy-5-fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 08).
- 2-[3-{4-(2-Ethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 09).
- 2-[3-{4-(2,4-Difluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 10).
- 2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 11).
- 2-[3-{4-(2-Methyl-5-chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 12).
- 2-[3-{4-(Phenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 13).
- 2-[3-{4-(Benzyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 14).
- 2-[3-{4-(Cinnamyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 15).
- 2-[3-{4-(4-Nitrophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 16).
- 2-[3-{4-(3-Chloro-4-methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 17).
- 2-[3-{4-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 18).
- 2-[3-{4-(Bis-4-fluorophenyl)methylpiperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 19).
- 2-[3-{4-(2,4-Dichlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 20).

- 2-[3-{4-(2,4-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 21).
- 2-[3-{4-(2,6-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 22).
- 2-[3-{4-(2-Isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 23).
- 2-[3-{4-(2-Propoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 24).
- 2-[3-{4-(2-n-Hexyloxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 25).
- 2-[3-{4-(2,5-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 26).
- 2-[3-{4-(4-tert-Butylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 27).
- 2-[3-{4-(2-Methoxy-6-hydroxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 28).
- 2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 29).
- 2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-2-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 30).
- 2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 31).

4. A method of selectively antagonizing  $\alpha_1$ -adrenergic receptors in a mammal comprising administering to said mammal a compound having the structure of Formula I

5




10

FORMULA - I

its pharmaceutically acceptable salts, amides, enantiomers, diastereomers, N-oxides, prodrugs, metabolites or their polymorphs, wherein A is a straight or branched C<sub>1</sub>-C<sub>4</sub> alkyl chain; R is cinnamyl, benzyl, substituted benzyl, phenyl, mono- or disubstituted phenyl group substituted with the substituents 5 independently selected from the group consisting of halogen, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, trifluoromethyl, nitro, trifluoroalkoxy group, or (dihalodiphenyl) methyl.

5. A method for treating benign prostatic hyperplasia in a mammal 10 comprising administering to said mammal a compound having the structure of Formula I

15



**FORMULA - I**

20 its pharmaceutically acceptable salts, amides, enantiomers, diastereomers, N-oxides, prodrugs, metabolites or their polymorphs, wherein A is a straight or branched C<sub>1</sub>-C<sub>4</sub> alkyl chain; R is cinnamyl, benzyl, substituted benzyl, phenyl, mono- or disubstituted with the substituents independently selected from the group 25 consisting of halogen, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, trifluoromethyl, nitro, trifluoroalkoxy group, or (dihalodiphenyl) methyl.


6. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutical acceptable carrier.

7. A method of selectively antagonizing  $\alpha_1$ -adrenergic receptors in a 30 mammal comprising the step of administering to the said mammal the pharmaceutical composition according to claim 6.

8. A method for treating benign prostatic hyperplasia in a mammal comprising the step of administering to the said mammal the pharmaceutical composition according to claim 6.

9. A process for preparing a compound of Formula I

5




10

**FORMULA - I**

or its pharmaceutically acceptable salts, amides, enantiomers, diastereomers, N-oxides, prodrugs, metabolites or their polymorphs, wherein A is a straight or branched C<sub>1</sub>-C<sub>4</sub> alkyl chain; R is cinnamyl, benzyl, substituted benzyl, phenyl, 15 mono- or disubstituted phenyl group substituted with the substituents independently selected from the group consisting of halogen, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, trifluoromethyl, nitro, trifluoroalkoxy group, or (dihalodiphenyl) methyl, which comprises reacting a compound of Formula II, with piperazine derivatives of Formula III, as shown in Scheme I wherein A 20 and R are the same as defined above.

10. A process for preparing a compound of Formula I

25



**FORMULA - I**

or its pharmaceutically acceptable salts, amides, enantiomers, diastereomers, N-oxides, prodrugs, metabolites or their polymorphs, wherein A is a straight or

branched C<sub>1</sub>-C<sub>4</sub> alkyl chain; R is cinnamyl, benzyl, substituted benzyl, phenyl, mono- or disubstituted phenyl group substituted with the substituents independently selected from the group consisting of halogen, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, trifluoromethyl, nitro, trifluoroalkoxy group or 5 (dihalodiphenyl) methyl, which comprises reacting 1-( $\omega$ -haloalkyl)cis-3a,4,7,7a-tetrahydronaphthalimide of Formula IV, wherein A is the same as defined above, with a compound of Formula V, wherein R is the same as defined above, as shown in Scheme II.

## INTERNATIONAL SEARCH REPORT

Intel' nal Application No  
PCT/IB 01/02261A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C07D209/48 A61K31/40 A61P13/08

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	U. V. KRGAONKAR ET AL.: "Synthesis of N-'3-(4-Aryl-1-piperazinyl)propyl-4,4-bis (4-methoxyphenyl)piperidin-2,6-diones/Tetrahydropthalimides/Camphorimides as Sedatives" J. INDIAN. CHEM. SOC., vol. LX, no. 9, 1983, pages 874-876, XP001062943 cited in the application table 1 ---	1,2
X	R. N. ZAGIDULLIN: "N-(.beta.-Aminoethyl)piperazine and its derivatives in aminomethylation reactions" ZH. OBSHCH. KHIM., vol. 61, no. 1, 1991, pages 247-253, XP001062785 * compound of formula VIIIb * ---	1,2 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the International search

Date of mailing of the International search report

18 April 2002

03/05/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel: (+31-70) 340-2040, Tx: 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Herz, C

## INTERNATIONAL SEARCH REPORT

Intel.inal Application No  
PCT/IB 01/02261

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6 090 809 A (N. ANAND ET AL.) 18 July 2000 (2000-07-18) cited in the application claims 1-8 ---	1-10
Y	US 6 083 950 A (N. ANAND ET AL.) 4 July 2000 (2000-07-04) cited in the application claims 1-8 ---	1-10
A	WO 98 51298 A (ORTHO-MCNEIL PHARMACEUTICAL INC.) 19 November 1998 (1998-11-19) claims 1-25 ---	1-10
A	EP 0 711 757 A (F. HOFFMANN-LA ROCHE AG) 15 May 1996 (1996-05-15) claims 1-22 ---	1-10
X	R. N. ZAGIDULLIN: "N-(.beta.)-Ethylaminopiperazine) and its derivatives in a Mannich reaction" KHIM. VYSOKOMOL. SOEDIN. NEFTEKHIM., 1973, pages 44-45, XP001062241 * compounds of formula 14 *	1,2
A	B. KENNY ET AL.: "Pharmacological Options in the Treatment of Benign Prostatic Hyperplasia" J. MED. CHEM., vol. 40, no. 9, 1997, pages 1293-1315, XP002195160 tables 3-17 ---	1-10
A	AT 387 773 B (BRISTOL-MEYERS CO.) 10 March 1989 (1989-03-10) claims 1-14 ---	1-10
A	US 4 524 206 A (J. S. NEW, J. P. YEVICH) 18 June 1985 (1985-06-18) cited in the application claims 1-23 ---	1-10
A	US 4 479 954 A (N. HIROSE ET AL.) 30 October 1984 (1984-10-30) claims 1-43 ---	1-10
A	US 4 598 078 A (K. ISHIZUMI ET AL.) 1 July 1986 (1986-07-01) cited in the application claims 1-18 ---	1-10
A	EP 0 109 562 A (SUMITOMO CHEMICAL CO., LTD.) 30 May 1984 (1984-05-30) claims 1-7 ---	1-10
		-/-

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IB 01/02261

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 111 226 A (EISAI CO., LTD.) 20 June 1984 (1984-06-20) claims 1-42 -----	1-10
A	PATENT ABSTRACTS OF JAPAN vol. 008, no. 126, 13 June 1984 (1984-06-13) & JP 59 036661 A (EISAI CO., LTD.) abstract -----	1-10

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Int'l Application No  
PCT/IB 01/02261

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 6090809	A	18-07-2000	US	6083950 A	04-07-2000
			AU	1979799 A	14-02-2000
			AU	4641099 A	14-02-2000
			BR	9912318 A	02-05-2001
			CN	1318052 T	17-10-2001
			CZ	20010235 A3	15-08-2001
			EP	1097134 A1	09-05-2001
			HU	0102980 A2	28-12-2001
			WO	0005206 A1	03-02-2000
			WO	0005205 A1	03-02-2000
			PL	345562 A1	17-12-2001
			SK	932001 A3	06-08-2001
US 6083950	A	04-07-2000	US	6090809 A	18-07-2000
WO 9851298	A	19-11-1998	AU	7366998 A	08-12-1998
			BR	9809804 A	27-06-2000
			CN	1264300 T	23-08-2000
			EP	0984777 A1	15-03-2000
			HU	0100048 A2	30-07-2001
			NO	995518 A	11-01-2000
			PL	342518 A1	18-06-2001
			TR	9902971 T2	21-03-2001
			US	6071915 A	06-06-2000
			WO	9851298 A1	19-11-1998
			US	6303594 B1	16-10-2001
			ZA	9803968 A	11-11-1999
EP 711757	A	15-05-1996	US	5688795 A	18-11-1997
			AU	3459995 A	16-05-1996
			BR	9505107 A	09-09-1997
			CA	2162089 A1	09-05-1996
			CN	1136039 A	20-11-1996
			CZ	9502910 A3	11-09-1996
			EP	0711757 A1	15-05-1996
			FI	955376 A	09-05-1996
			HU	73843 A2	30-09-1996
			JP	8208614 A	13-08-1996
			NO	954453 A	09-05-1996
			NZ	280396 A	26-05-1997
			PL	311261 A1	13-05-1996
			SG	70950 A1	21-03-2000
			TR	960469 A2	21-07-1996
AT 387773	B	10-03-1989	US	4524206 A	18-06-1985
			AT	291584 A	15-08-1988
			AU	581858 B2	09-03-1989
			AU	3287084 A	30-05-1985
			BE	900555 A1	11-03-1985
			CA	1285564 A1	02-07-1991
			CH	660484 A5	30-04-1987
			CS	8406721 A2	17-12-1987
			CS	8507792 A2	17-12-1987
			CY	1538 A	16-11-1990
			DD	224593 A5	10-07-1985
			DE	3433327 A1	28-03-1985
			DK	171990 B1	08-09-1997
			ES	535780 D0	01-04-1986

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/IB 01/02261

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
AT 387773	B	ES 8605797 A1 FI 843522 A ,B, FR 2555585 A1 GB 2146333 A ,B GR 80320 A1 HK 84590 A HU 36116 A2 IE 58020 B1 IL 72854 A IT 1196250 B JP 1922135 C JP 6047586 B JP 60084282 A KR 8900566 B1 LU 85537 A1 NL 8402769 A NO 843579 A ,B NZ 209480 A OA 7809 A PT 79187 A ,B SE 463368 B SE 8404552 A SU 1384199 A3 YU 156384 A1 YU 210386 A1 ZA 8407065 A	16-09-1986 13-03-1985 31-05-1985 17-04-1985 14-01-1985 25-10-1990 28-08-1985 30-06-1993 31-03-1988 16-11-1988 07-04-1995 22-06-1994 13-05-1985 21-03-1989 29-04-1985 01-04-1985 13-03-1985 08-01-1988 20-11-1986 01-10-1984 12-11-1990 13-03-1985 23-03-1988 28-02-1987 31-12-1987 24-04-1985
US 4524206	A 18-06-1985	AT 387773 B AT 291584 A AU 581858 B2 AU 3287084 A BE 900555 A1 CA 1285564 A1 CH 660484 A5 CS 8406721 A2 CS 8507792 A2 CY 1538 A DD 224593 A5 DE 3433327 A1 DK 171990 B1 ES 535780 D0 ES 8605797 A1 FI 843522 A ,B, FR 2555585 A1 GB 2146333 A ,B GR 80320 A1 HK 84590 A HU 36116 A2 IE 58020 B1 IL 72854 A IT 1196250 B JP 1922135 C JP 6047586 B JP 60084282 A KR 8900566 B1 LU 85537 A1 NL 8402769 A NO 843579 A ,B	10-03-1989 15-08-1988 09-03-1989 30-05-1985 11-03-1985 02-07-1991 30-04-1987 17-12-1987 17-12-1987 16-11-1990 10-07-1985 28-03-1985 08-09-1997 01-04-1986 16-09-1986 13-03-1985 31-05-1985 17-04-1985 14-01-1985 25-10-1990 28-08-1985 30-06-1993 31-03-1988 16-11-1988 07-04-1995 22-06-1994 13-05-1985 21-03-1989 29-04-1985 01-04-1985 13-03-1985

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Inte  
nal Application No  
**PCT/IB 01/02261**

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 4524206	A	NZ	209480 A	08-01-1988
		OA	7809 A	20-11-1986
		PT	79187 A , B	01-10-1984
		SE	463368 B	12-11-1990
		SE	8404552 A	13-03-1985
		SU	1384199 A3	23-03-1988
		YU	156384 A1	28-02-1987
		YU	210386 A1	31-12-1987
		ZA	8407065 A	24-04-1985
US 4479954	A	30-10-1984	JP 1603541 C	04-04-1991
			JP 2029671 B	02-07-1990
			JP 57197265 A	03-12-1982
			BE 893378 A1	01-12-1982
			CA 1211436 A1	16-09-1986
			CH 649287 A5	15-05-1985
			DE 3220262 A1	16-12-1982
			DK 241982 A	30-11-1982
			ES 512642 D0	01-09-1983
			ES 8308548 A1	01-12-1983
			ES 523205 D0	16-02-1985
			ES 8503343 A1	01-06-1985
			ES 537721 D0	16-10-1985
			ES 8601156 A1	16-02-1986
			FR 2506771 A1	03-12-1982
			GB 2101590 A , B	19-01-1983
			IT 1151781 B	24-12-1986
			KR 8701027 B1	25-05-1987
			KR 8800450 B1	06-04-1988
			KR 8800451 B1	06-04-1988
			NL 8202173 A	16-12-1982
			PH 19837 A	22-07-1986
			PH 19291 A	04-03-1986
			PH 19276 A	21-02-1986
			PH 19272 A	21-02-1986
			SE 450894 B	10-08-1987
			SE 8203272 A	30-11-1982
US 4598078	A	01-07-1986	JP 1639107 C	18-02-1992
			JP 3004069 B	22-01-1991
			JP 59076059 A	28-04-1984
			AT 29255 T	15-09-1987
			CA 1230597 A1	22-12-1987
			DE 3373306 D1	08-10-1987
			EP 0109562 A1	30-05-1984
EP 109562	A	30-05-1984	JP 1639107 C	18-02-1992
			JP 3004069 B	22-01-1991
			JP 59076059 A	28-04-1984
			AT 29255 T	15-09-1987
			CA 1230597 A1	22-12-1987
			DE 3373306 D1	08-10-1987
			EP 0109562 A1	30-05-1984
			US 4598078 A	01-07-1986
EP 111226	A	20-06-1984	JP 1720039 C	14-12-1992
			JP 4009782 B	21-02-1992
			JP 59095267 A	01-06-1984

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 01/02261

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 111226	A	AT 29716 T CA 1257596 A1 DE 3373652 D1 EP 0111226 A1 US 4567180 A	15-10-1987 18-07-1989 22-10-1987 20-06-1984 28-01-1986
JP 59036661	A	28-02-1984	NONE